Hugo M. Aarts

Hugo M. Aarts

Auto-generated profile, based on publicly available information

Hugo M. Aarts

Department of Cardiology, Amsterdam University Medical Centres, Amsterdam, the Netherlands; Department of Cardiology, University Medical Centre Utrecht, Utrecht, the Netherlands

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 January 2025 in JACC: Cardiovascular Interventions
Verified
Journal Article
Open access
HAHugo M. Aarts
Hugo M. Aarts
ANAstrid C. van Nieuwkerk
Astrid C. van Nieuwkerk
KHKimberley I. Hemelrijk
Kimberley I. Hemelrijk
JFJorge Salgado Fernandez
Jorge Salgado Fernandez
DTDidier Tchétché
Didier Tchétché
RDRonak Delewi
Ronak Delewi
Transcatheter aortic valve replacement (TAVR) harbors the risk of periprocedural complications that require emergent cardiac surgery, or "surgical bailout." Surgical bailout intends to be lifesaving but is associated with high mortality. This has given rise to discussion on the necessity of surgical backup during TAVR. Therefore, recent studies in contemporary TAVR patients are warranted. This study aimed to assess the incidence, trends, and clinical outcomes of surgical bailout in patients undergoing transfemoral TAVR. The CENTER2 (Cerebrovascular Events in Patients Undergoing Transcatheter Aortic Valve Implantation With Balloon-Expandable Valves Versus Self-Expandable Valves 2) study contains patient-level data from 10 clinical studies with patients undergoing TAVR between 2007 and 2022. A total of 24,010 patients undergoing transfemoral TAVR were included. The mean age was 81.5 ± 6.7 years, and 56% were female. The median Society of Thoracic Surgeons Predicted Risk of Mortality declined over time (2007-2014: 7.1% [Q1-Q3: 4.3%-14.8%] vs 2015-2022: 3.9% [Q1-Q3: 2.6%-6.0%]; P < 0.001). Surgical bailout was reported in 125 (0.52%) patients, and its incidence decreased over time, from 0.84% in 2007 to 2010 to 0.25% in 2019 to 2022 (Ptrend < 0.001). Surgical bailout was more frequently observed in women compared with men (0.61% vs 0.41%; P = 0.03). Ventricular perforation was the most prevalent reason for surgical bailout (28.0%). Patients who underwent surgical bailout reported higher mortality rates during the 1-year follow-up compared with patients without surgical bailout (68.3% vs 15.3%; HR: 8.60; 95% CI: 6.74-10.97; P < 0.001). Interestingly, patients surviving the first 90 days reported a similar mortality risk (HR: 2.19; 95% CI: 0.91-5.27; P = 0.08). The incidence of surgical bailout is very low in the contemporary TAVR population. Mortality rates remain high among patients requiring surgical bailout during transfemoral TAVR, but this risk diminishes in patients surviving the postprocedural period. (Cerebrovascular Events in Patients Undergoing Transcatheter Aortic Valve Implantation With Balloon-Expandable Valves Versus Self-Expandable Valves 2 [CENTER2]; NCT03588247).

3 September 2024 in Journal of the American Heart Association
Verified
Journal Article
Open access
ANAstrid van Nieuwkerk
Astrid van Nieuwkerk
HAHugo M. Aarts
Hugo M. Aarts
KHKimberley I. Hemelrijk
Kimberley I. Hemelrijk
CCCristobal Urbano Carrillo
Cristobal Urbano Carrillo
DTDidier Tchétché
Didier Tchétché
RDRonak Delewi
Ronak Delewi
Background: Cerebrovascular events remain one of the most devastating complications of transcatheter aortic valve implantation (TAVI). Data from real‐world contemporary cohorts on longitudinal trends and outcomes remain limited. The aim of this study was to assess incidence, temporal trends, predictors, and outcomes of cerebrovascular events following transfemoral TAVI. Methods and Results: The CENTER2 (Cerebrovascular Events in Patients Undergoing Transcatheter Aortic Valve Implantation With Balloon‐Expandable Valves Versus Self‐Expandable Valves 2) study includes patients undergoing TAVI between 2007 and 2022. The database contains pooled patient‐level data from 10 clinical studies. A total of 24 305 patients underwent transfemoral TAVI (mean age 81.5±6.7 years, 56% women, median Society of Thoracic Surgeon Predicted Risk of Mortality 4.9% [3.1%–8.5%]). Of these patients, 2.2% (n=534) experienced stroke in the first 30 days after TAVI, and 40 (0.4%) had a transient ischemic attack. Stroke rates remained stable during the treatment period (2007–2010: 2.1%, 2011–2014: 2.5%, 2015–2018: 2.1%, 2019–2022: 2.1%; P trend =0.28). Moreover, 30‐day cerebrovascular event rates were similar across Society of Thoracic Surgeon Predicted Risk of Mortality risk categories: 2.1% in low‐risk, 2.6% in intermediate‐risk, and 2.5% in high‐risk patients ( P =0.21). Mortality was higher in patients with 30‐day stroke than without at 30 days (20.3% versus 4.7%; odds ratio, 5.1 [95% CI, 4.1–6.5]; P <0.001) and at 1 year (44.1% versus 15.0%; hazard ratio, 3.5 [95% CI, 3.0–4.2]; P <0.001). One‐year mortality rates for stroke did not decline over time (2007–2010: 46.9%, 2011–2014: 46.0%, 2015–2018: 43.0%, 2019–2022: 39.1%; P trend =0.32). At 1 year, 7.0% of patients undergoing TAVI had a stroke. Conclusions: In 24 305 patients who underwent transfemoral TAVI, 30‐day cerebrovascular event incidence remained ≈ 2.2% between 2007 and 2022. Thirty‐day stroke rates were similar throughout Society of Thoracic Surgeon Predicted Risk of Mortality risk categories. Mortality rates after stroke remain high. Registration: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT03588247.

16 December 2024 in American Heart Journal
Verified
Journal Article
Open access
HAHugo M. Aarts
Hugo M. Aarts
KHKimberley I. Hemelrijk
Kimberley I. Hemelrijk
GBGijs M. Broeze
Gijs M. Broeze
DGDirk Jan van Ginkel
Dirk Jan van Ginkel
GVGeert A.A. Versteeg
Geert A.A. Versteeg
MVMichiel Voskuil
Michiel Voskuil
Concomitant coronary artery disease (CAD) is highly prevalent in patients with severe aortic stenosis undergoing transcatheter aortic valve implantation (TAVI). The optimal treatment strategy for CAD is a topic of debate. An initial conservative strategy for CAD in patients undergoing TAVI may be favorable as multiple studies have failed to show an evident beneficial effect of percutaneous coronary intervention (PCI) on mortality after TAVI. However, more randomized, controlled trials are warranted. The PeRcutaneous cOronary Intervention before Transcatheter Aortic Valve Implantation (PRO-TAVI) trial is an investigator-initiated, multicenter, open-label, randomized controlled trial comparing TAVI with or without routine preprocedural PCI. A total of 466 patients undergoing TAVI will be randomized in a 1:1 ratio to PCI (reference group) or no PCI (index group). Concomitant CAD is defined as at least 1 stenosis of 70% to 99%, or at least 1 stenosis between 40% and 70% combined with positive physiological measurement in a coronary artery with a minimal diameter of 2.5 mm or bypass graft. The primary endpoint is a composite of all-cause mortality, myocardial infarction, stroke, or type 2 - 4 bleeding at 12 months after randomization, in accordance with Valve Academic Research Consortium-3 criteria. Key secondary endpoints include the individual components of the primary endpoint, revascularization, quality of life and cost-effectiveness. The primary endpoint will be analyzed to assess non-inferiority of deferral of routine PCI in patients undergoing TAVI against the prespecified margin of 11 percentage points. The PeRcutaneous cOronary intervention before Transcatheter Aortic Valve Implantation (PRO-TAVI) trial is designed to investigate the hypothesis that deferral of routine PCI in patients undergoing TAVI is non-inferior to TAVI with preceding PCI. clinicaltrials.gov. Unique identifier NCT05078619.


10 February 2026 in Structural Heart
Verified
Journal Article
Open access
KHKimberley I. Hemelrijk
Kimberley I. Hemelrijk
HAHugo M. Aarts
Hugo M. Aarts
GBGijs M. Broeze
Gijs M. Broeze
AMAntonio Gomez Menchero
Antonio Gomez Menchero
DTDidier Tchétché
Didier Tchétché
RDRonak Delewi
Ronak Delewi
Transcatheter aortic valve replacement (TAVR) is an effective treatment in patients with “classical” concordant high-gradient aortic stenosis (AS). However, data on outcomes in patients with discordant AS are scarce. Our study aims to investigate the clinical outcomes of patients undergoing TAVR with different types of AS. The Cerebrovascular Events in Patients Undergoing Transcatheter Aortic Valve Implantation 2 (CENTER2) study is a patient-level database including 25,771 patients who underwent TAVR, of whom 15,233 were included in this analysis. Four AS subgroups were identified, and patients were classified as discordant AS (low-gradient AS with preserved or impaired left ventricular ejection fraction [LVEF] or discordant high-gradient AS) or concordant high-gradient AS. A total of 15,233 patients underwent TAVR. The mean age was 81.5 ± 6.8 years, 56% were women, and Society of Thoracic Surgeons Predicted Risk of Mortality was 4.8% (interquartile range [IQR] 3.0-8.0%). Of these, 2731 (17.9%) patients had low-gradient AS with preserved or impaired LVEF, 138 (0.9%) discordant high-gradient AS, and 12,364 (81.2%) concordant high-gradient AS. There was no difference in 1-year mortality between discordant AS and concordant high-gradient AS (13.1 vs. 11.9%, adjusted hazard ratio 1.19, p = 0.08). One-year mortality rates was higher in low-gradient AS with impaired LVEF compared to concordant high-gradient AS (15.9 vs. 11.9%, adjusted hazard ratio 1.43, p = 0.01). Patients with concordant high-gradient AS had higher major bleeding rates (6.7%) compared to both low-gradient AS with impaired LVEF (4.0%) and preserved LVEF (5.4%) (p < 0.001 and p = 0.04). Nearly 20% of patients undergoing TAVR had discordant AS. One-year mortality was higher in low-gradient AS with impaired LVEF, whereas outcomes were similar among low-gradient with preserved LVEF, discordant high-gradient, and concordant high-gradient AS.

10 December 2025 in Catheterization and Cardiovascular Interventions
Verified
Journal Article
Open access
HAHugo M. Aarts
Hugo M. Aarts
KHKimberley I. Hemelrijk
Kimberley I. Hemelrijk
GBGijs M. Broeze
Gijs M. Broeze
SMSteven A. Muller
Steven A. Muller
LDLineke Derks
Lineke Derks
TRThe Transcatheter Heart Intervention And Percutaneous Coronary Intervention Registration Committees Of The Netherlands Heart Registration
The Transcatheter Heart Intervention And Percutaneous Coronary Intervention Registration Committees Of The Netherlands Heart Registration
Background: Percutaneous coronary intervention (PCI) after transcatheter aortic valve replacement (TAVR) has gained interest as concomitant coronary artery disease (CAD) is now often treated conservatively before TAVR, and TAVR is increasingly used in younger patients with longer life expectancies. Therefore, more contemporary data on PCI after TAVR are warranted to optimize CAD treatment and guide lifetime management. The primary objective was to evaluate the incidence of PCI in patients with prior TAVR, including insights on trends and procedural and clinical outcomes from a large, nationwide cohort. Methods: Data from the Netherlands Heart Registration were used to identify patients with prior TAVR who underwent PCI between January 2015 and September 2021. Results: Among 216,813 PCI patients, 419 (0.19%) had previously undergone TAVR, representing an incidence of 2.81% among all TAVR patients ( n = 14,933) in the Netherlands. The annual proportion of PCI procedures after TAVR increased from 0.05% in 2015 to 0.39% in 2021 ( p < 0.001). Procedural adverse events were low. Patients treated with self‐expanding transcatheter heart valves (THVs) more frequently underwent PCI without stenting (17.8% vs. 10.1%, p = 0.049), though target vessel revascularization rates and all‐cause mortality were comparable. Matched patients with and without prior TAVR had similar clinical outcomes. Conclusions: The incidence of PCI after TAVR is low but increasing. Clinical outcomes are comparable between THV platforms, but self‐expanding THVs were associated with higher rates of PCI without stent implantation. The growing need for PCI after TAVR underscores the importance of coronary access in lifetime management strategies by multidisciplinary heart teams.